US2004266989A1PendingUtilityA1
Methods and compositions for the treatment of gastrointestinal disorders
Est. expiryJan 28, 2023(expired)· nominal 20-yr term from priority
A61P 35/04A61P 43/00A61P 3/10A61P 9/00A61P 5/50A61P 9/04A61P 9/10A61P 7/10A61P 3/00A61P 25/24A61P 25/00A61P 29/00A61P 25/04A61P 25/28A61P 25/22A61P 3/12A61P 35/00A61P 35/02A61P 3/04A61P 25/20A61P 27/16A61P 25/18A61P 1/18A61P 1/12A61P 15/10A61P 13/12A61P 1/00A61P 1/16A61P 1/10A61P 1/08A61P 1/04A61P 13/08A61P 11/00A61P 1/14A61P 13/00A61P 11/06A61K 38/00C07K 14/245C07K 7/08A61K 38/10C07K 7/06
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC—C) receptor.
Claims
exact text as granted — not AI-modified1 . A purified peptide comprising the amino acid sequence (I): Xaa 1 Xaa 2 Xaa 3 Xaa 4 Xaa 5 Cys 6 Cys 7 Xaa 8 Xaa 9 Cys 10 Cys 11 Xaa 12 Xaa 13 Xaa 14 Cys 15 Xaa 16 Xaa 17 Cys 18 Xaa 1 Xaa 20 Xaa 21 (SEQ ID NO:119) wherein: Xaa 1 Xaa 2 Xaa 3 Xaa 4 Xaa 5 is Asn Ser Ser Asn Tyr (SEQ ID NO:121 )or is missing or Xaa 1 Xaa 2 Xaa 3 Xaa 4 is missing.
2 . The purified peptide of claim 1 wherein Xaa 5 is Asn, Trp, Tyr, Asp, or Phe.
3 . The purified peptide of claim 1 wherein Xaa 5 is Thr or Ile.
4 . The purified peptide of claim 1 wherein Xaa 5 is Tyr, Asp or Trp.
5 . The purified peptide of claim 1 wherein Xaa 8 is Glu, Asp, Gln, Gly or Pro.
6 . The purified peptide of claim 1 wherein Xaa 9 is Leu, Ile, Val, Ala, Lys, Arg, Trp, Tyr or Phe.
7 . The purified peptide of claim 1 wherein Xaa 9 is Leu, Ile, Val, Lys, Arg, Trp, Tyr or Phe.
8 . The purified peptide of claim 1 wherein Xaa 12 is Asn, Tyr, Asp or Ala.
9 . The purified peptide of claim 1 wherein Xaa 13 is Ala, Pro or Gly.
10 . The purified peptide of claim 1 wherein Xaa 14 is Ala, Leu, Ser, Gly, Val, Glu, Gln, Ile, Leu, Lys, Arg, or Asp.
11 . The purified peptide of claim 1 wherein Xaa 16 is Thr, Ala, Asn, Lys, Arg, Trp.
12 . The purified peptide of claim 1 wherein Xaa 17 is Gly, Pro or Ala.
13 . The purified peptide of claim 1 wherein Xaa 19 is Trp, Tyr, Phe, Asn or Leu.
14 . The purified peptide of claim 1 wherein Xaa 19 is Lys or Arg.
15 . The purified peptide of claim 1 wherein Xaa 20 Xaa 21 is AspPhe or Xaa 20 is Asn or Glu and Xaa 21 is missing.
16 . A purified peptide comprising the amino acid sequence:
Asn Ser Ser Asn Tyr Cys Cys
(SEQ ID NO:[[---]] 28 ;
Glu Tyr Cys Cys Asn Pro Ala
MD-915)
Cys Thr Gly Cys Tyr.
17 . A purified peptide comprising the amino acid sequence:
Cys Cys Glu Tyr Cys Cys Asn
(SEQ ID NO:[[--]] 31 ;
Pro Ala Cys Thr Gly Cys Tyr.
MD-1100)
18 . A purified peptide consisting of the amino acid sequence:
Asn Ser Ser Asn Tyr Cys Cys
(SEQ ID NO:[[--]] 28
Glu Tyr Cys Cys Asn Pro Ala
MD-915)
Cys Thr Gly Cys Tyr.
19 . A purified peptide consisting of the amino acid sequence:
Cys Cys Glu Tyr Cys Cys Asn
(SEQ ID NO:[[--]] 31 ;
Pro Ala Cys Thr Gly Cys Tyr.
MD-1100)
20 . A method for treating a gastrointestinal disorder in a patient comprising administering a purified peptide comprising the amino acid sequence:
Asn Ser Ser Asn Tyr Cys Cys
[SEQ ID NO:[[--]] 26 ;
Glu Leu Cys Cys Asn Pro Ala
MM-416776)
Cys Thr Gly Cys Tyr.
21 . A method for treating a gastrointestinal disorder in a patient comprising administering a purified peptide comprising the amino acid sequence:
Asn Ser Ser Asn Tyr Cys Cys
(SEQ ID NO:[[---]] 28 ;
Glu Tyr Cys Cys Asn Pro Ala
MD-915)
Cys Thr Gly Cys Tyr.
22 . A method for treating a gastrointestinal disorder in a patient comprising administering a purified peptide comprising the amino acid sequence:
Cys Cys Glu Leu Cys Cys Asn
(SEQ ID NO:[[--]] 29 ;
Pro Ala Cys Thr Gly Cys Tyr
MM416774)
23 . A method for treating a gastrointestinal disorder in a patient comprising administering a purified peptide comprising the amino acid sequence:
Cys Cys Glu Tyr Cys Cys Asn
(SEQ ID NO:[[--]] 29 ;
Pro Ala Cys Thr Gly Cys Tyr.
MD-1100)
24 . A purified polypeptide comprising an amino acid sequence of any of:
Asn Ser Ser Asn Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Trp Gly Cys Tyr;
(SEQ ID NO:[[--]] 27 )
Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Trp Gly Cys Tyr;
(SEQ ID NO:[---] 30 )
Asn Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO:[[---] 32 )
Asn Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Trp Gly Cys Tyr;
(SEQ ID NO:[---] 33 )
Asn Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO:[---] 34 )
Asn Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO:[---] 35 )
Asn Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO:[---] 36 )
Asn Cys Cys Glu Arg Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO:[---] 37 )
Asn Cys Cys Glu Lys Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO:[---] 38 )
Asn Ser Ser Asn Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp
(SEQ ID NO:[---] 39 )
Phe;
Asn Ser Ser Asn Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Trp Gly Cys Tyr Asp
(SEQ ID NO:[---] 40 )
Phe;
Asn Ser Ser Asn Tyr Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp
(SEQ ID NO:[---] 41 )
Phe;
Asn Ser Ser Asn Tyr Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp
(SEQ ID NO:[---] 42 )
Phe;
Asn Ser Ser Asn Tyr Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp
(SEQ ID NO:[---] 43 )
Phe;
Asn Ser Ser Asn Tyr Cys Cys Glu Arg Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp
(SEQ ID NO:[---] 44 )
Phe;
Asn Ser Ser Asn Tyr Cys Cys Glu Lys Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp
(SEQ ID NO:[---] 45 )
Phe;
Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp Phe;
(SEQ ID NO:[---] 46 )
Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Trp Gly Cys Tyr Asp Phe;
(SEQ ID NO:[---] 47 )
Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp Phe;
(SEQ ID NO:[---] 48 )
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp Phe;
(SEQ ID NO:[---] 49 )
Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp Phe;
(SEQ ID NO:[---] 50 )
Cys Cys Glu Arg Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp Phe;
(SEQ ID NO:[---] 51 )
Cys Cys Glu Lys Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp Phe;
(SEQ ID NO:[--] 52 )
Asn Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp Phe;
(SEQ ID NO:[--]) 53
Asn Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Trp Gly Cys Tyr Asp Phe;
(SEQ ID NO: [---]) 54
Asn Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp Phe;
(SEQ ID NO:[---] 55 )
Asn Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp Phe;
(SEQ ID NO:[---] 56 )
Asn Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp Phe;
(SEQ ID NO:[---] 57 )
Asn Cys Cys Glu Arg Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp Phe;
(SEQ ID NO:[---] 58 )
Asn Cys Cys Glu Lys Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp Phe;
(SEQ ID NO:[---] 59 )
Gln Ser Ser Asn Tyr Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO:[---] 67 )
Asn Thr Ser Asn Tyr Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO:[---] 68 )
Asn Leu Ser Asn Tyr Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO:[---] 69 )
Asn Ile Ser Asn Tyr Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO:[---] 70 )
Asn Ser Ser Gln Tyr Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO:[---] 71 )
Ser Ser Asn Tyr Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO:[---] 72 )
Gln Ser Ser Gln Tyr Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO:[---] 73 )
Ser Ser Gln Tyr Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO:[---] 74 )
Asn Ser Ser Asn Tyr Cys Cys Glu Ala Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 75 )
Asn Ser Ser Asn Tyr Cys Cys Glu Arg Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 76 )
Asn Ser Ser Asn Tyr Cys Cys Glu Asn Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 77 )
Asn Ser Ser Asn Tyr Cys Cys Glu Asp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 78 )
Asn Ser Ser Asn Tyr Cys Cys Glu Cys Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 79 )
Asn Ser Ser Asn Tyr Cys Cys Glu Gln Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 80 )
Asn Ser Ser Asn Tyr Cys Cys Glu Glu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 81 )
Asn Ser Ser Asn Tyr Cys Cys Glu Gly Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 82 )
Asn Ser Ser Asn Tyr Cys Cys Glu His Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 83 )
Asn Ser Ser Asn Tyr Cys Cys Glu Ile Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 84 )
Asn Ser Ser Asn Tyr Cys Cys Glu Lys Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 85 )
Asn Ser Ser Asn Tyr Cys Cys Glu Met Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 86 )
Asn Ser Ser Asn Tyr Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 87 )
Asn Ser Ser Asn Tyr Cys Cys Glu Pro Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 88 )
Asn Ser Ser Asn Tyr Cys Cys Glu Ser Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 89 )
Asn Ser Ser Asn Tyr Cys Cys Glu Thr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 90 )
Asn Ser Ser Asn Tyr Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 91 )
Asn Ser Ser Asn Tyr Cys Cys Glu Val Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 92 )
Cys Cys Glu Ala Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 93 )
Cys Cys Glu Arg Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 94 )
Cys Cys Glu Asn Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 95 )
Cys Cys Glu Asp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 96 )
Cys Cys Glu Cys Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 97 )
Cys Cys Glu Gln Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 98 )
Cys Cys Glu Glu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 99 )
Cys Cys Glu Gly Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 100 )
Cys Cys Glu His Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 101 )
Cys Cys Glu Ile Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 102 )
Cys Cys Glu Lys Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 103 )
Cys Cys Glu Met Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 104 )
Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 105 )
Cys Cys Glu Pro Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 106 )
Cys Cys Glu Ser Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 107 )
Cys Cys Glu Thr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 108 )
Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 109 )
Cys Cys Glu Val Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO: 110 )
Asn Ser Ser Asn Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO:[--] 26 ;
and
MM-416776)
Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr.
(SEQ ID NO:[--] 29 ;
MM416774)
25 . A method for treating a gastrointestinal disorder in a patient comprising administering the peptide of claim 1 .
26 . A method for treating a gastrointestinal disorder in a patient comprising administering the peptide of claim 24 .
27 . The method of any of claims 20 - 26 wherein the gastrointestinal disorder is a gastrointestinal motility disorder.
28 . The method of any of claims 20 - 26 wherein the gastrointestinal disorder is selected from the group consisting of a gastrointestinal motility disorder, irritable bowel syndrome, chronic constipation, a functional gastrointestinal disorder, gastroesophageal reflux disease, functional heartburn, dyspepsia, functional dyspepsia, nonulcer dyspepsia, gastroparesis, chronic intestinal pseudo-obstruction, colonic pseudo-obstruction, Crohn's disease, ulcerative colitis, and inflammatory bowel disease.
29 . A method for treating obesity comprising administering the peptide of any of claims 1 , 16 - 19 , and 24 .
30 . A method for treating congestive heart failure comprising administering the peptide of any of claims 1 , 16 - 19 , and 24 .
31 . A method for treating benign prostatic hyperplasia comprising administering the peptide of any of claims 1 , 16 - 19 , and 24 .
32 . The purified peptide of any of claims 1 , 16 , 17 , and 24 wherein the polypeptide comprises the amino acid sequence DF; QHNPR (SEQ ID NO: 111 ); VQHNPR (SEQ ID NO: 112 ); VRQHNPR (SEQ ID NO: 113 ); VRGQHNPR (SEQ ID NO: 114 ); VRGPQHNPR (SEQ ID NO: 115 ); VRGPRQHNPR (SEQ ID NO: 116 ); VRGPRRQHNPR (SEQ ID NO: 117 ); or RQHNPR (SEQ ID NO: 118 ) fused to its amino terminus or its caboxy terminus.
33 . The purified peptide of any of claims 1 , 16 , 17 , and 24 wherein the purified polypeptide comprises the amino acid sequence of an analgesic peptide selected from the group consisting of endomorphin-1, endomorphin-2, nocistatin, dalargin, lupron, and substance P fused to its amino terminus or its carboxy terminus.
34 . The purified peptide of any of claims 1 , 16 , 17 , and 24 wherein the polypeptide includes no more than 10 additional amino acids at its amino terminus or carboxy terminus or both and wherein the polypeptide is a guanylate cyclase receptor agonist.
35 . The purified peptide of claim 1 wherein wherein: Xaa 1 Xaa 2 Xaa 3 Xaa 4 Xaa 5 is missing; Xaa 8 is Glu; Xaa 9 is Leu, Ile, Lys, Arg, Trp, Tyr or Phe; Xaa 12 is Asn; Xaa 13 is Pro; Xaa 14 is Ala; Xaa 16 is Thr, Ala, Lys, Arg, Trp; Xaa 17 is Gly; Xaa 19 is Tyr or Leu; and Xaa 20 Xaa 21 is AspPhe or is missing.
36 . A method for treating a patient suffering from constipation, the method comprising administering the polypeptide of any of claims 1 , 16 - 23 and 28 .
37 . A method for increasing the activity of an intestinal guanylate cyclase (GC—C) receptor in a patient, the method comprising administering the polypeptide of any of claims 1 , 16 - 19 and 24 .
38 . A method for treating a gastrointestinal disorder in a patient comprising administering a GC—C receptor agonist.
39 . The method of claim 38 wherein the gastrointestinal disorder is a gastrointestinal motility disorder.
40 . The method of claim 38 wherein the gastrointestinal disorder is selected from the group consisting of a gastrointestinal motility disorder, irritable bowel syndrome, chronic constipation, a functional gastrointestinal disorder, gastroesophageal reflux disease, functional heartburn, dyspepsia, functional dyspepsia, nonulcer dyspepsia, gastroparesis, chronic intestinal pseudo-obstruction, colonic pseudo-obstruction, Crohn's disease, ulcerative colitis, and inflammatory bowel disease.
41 . A method for treating obesity comprising administering a GC—C receptor agonist.
42 . A method for treating congestive heart failure comprising administering a GC—C receptor agonist.
43 . A method for treating benign prostatic hyperplasia comprising administering a GC—C receptor agonist.
44 . A method for treating visceral pain comprising administering a GC—C receptor agonist.
45 . A method for treating inflammation comprising administering a GC—C receptor agonist.
46 . A method for treating constipation comprising administering a GC—C receptor agonist.
47 . A method for treating visceral pain comprising administering the polypeptide of any of claims 1 , 16 - 19 and 24 .
48 . A method for treating inflammation comprising administering the polypeptide of any of claims 1 , 16 - 19 and 24 .
49 . A method for treating cystic fibrosis comprising administering the polypeptide of any of claims 1 , 16 - 19 and 24 .
50 . A method for treating cystic fibrosis comprising administering a GC—C receptor agonist.
51 . A pharmaceutical composition comprising the peptide of any of claims 1 , 16 - 19 and 24 and a pharmaceutically acceptable carrier.
52 . A pharmaceutical composition comprising the peptide of any of claims 1 , 16 - 19 and 24 surrounded by an enteric coating.
53 . A controlled release pharmaceutical composition comprising the peptide of any of claims 1 , 16 - 19 and 24 and a biodegradable polymeric matrix.
54 . A pharmaceutical composition comprising the peptide of any of claims 1 , 16 - 19 and 24 , an analgesic agent and a pharmaceutically acceptable carrier.
55 . A pharmaceutical composition comprising the peptide of any of claims 1 , 16 - 19 and 24 , a phosphodiesterase inhibitor and a pharmaceutically acceptable carrier.
56 . A method for treating cancer, a respiratory disorder, a neurological disorder, a disorder associated with fluid and sodium retention, a disorder associated with carbonate imbalance, erectile dysfunction, an insulin-related disorder, or an inner ear disorder, the method comprising administering the peptide of any of claims 1 , 16 - 19 and 24 .
57 . A method for treating cancer, a respiratory disorder, a neurological disorder, a disorder associated with fluid and sodium retention, a disorder associated with carbonate imbalance, erectile dysfunction, an insulin-related disorder, or an inner ear disorder, the method comprising administering a GC—C receptor agonist.
58 . A method of producing the peptide of any of claims 16 - 19 and 24 , comprising providing a cell harboring a nucleic acid molecule encoding the polypeptide, culturing the cell under conditions in which the peptide is expressed, and isolating the expressed peptide.
59 . A method of producing the peptide of any of claims 16 - 19 and 24 , comprising chemically synthesizing the peptide and they purifying the synthesized peptide.
60 . A pharmaceutical composition comprising the peptide of any of claims 1 , 16 - 19 and 24 and a natriuretic peptide such as atrial natriuretic peptide, brain natriuretic peptide, a C-type natriuretic peptide, a diuretic, or an inhibitor of angiotensin converting enzyme.
61 . A pharmaceutical composition comprising the peptide of any of claims 1 , 16 - 19 and 24 and a 5-alpha reductase inhibitor or an alpha adrenergic inhibitor.
62 . A pharmaceutical composition comprising the peptide of any of claims 1 , 16 - 19 and 24 and gut hormone fragment peptide YY 3-36 , glp-1 (glucagon-like peptide-1), exendin-4 (an inhibitor of glp-1), sibutramine, phentermine, phendimetrazine, benzphetamine hydrochloride (Didrex), orlistat (Xenical), diethylpropion hydrochloride (Tenuate), fluoxetine (Prozac), bupropion, ephedra, chromium, garcinia cambogia, benzocaine, bladderwrack (focus vesiculosus), chitosan, nomame herba, galega (Goat's Rue, French Lilac), conjugated linoleic acid, L-carnitine, fiber (psyllium, plantago, guar fiber), caffeine, dehydroepiandrosterone, germander (teucrium chamaedrys), B-hydroxy-β-methylbutyrate, or pyruvate.
63 . A pharmaceutical composition comprising a GC—C receptor agonist and a natriuretic peptide such as atrial natriuretic peptide, brain natriuretic peptide, a C-type natriuretic peptide, a diuretic, or an inhibitor of angiotensin converting enzyme.
64 . A pharmaceutical composition comprising a GC—C receptor agonist and a 5-alpha reductase inhibitor or an alpha adrenergic inhibitor.
65 . A pharmaceutical composition comprising a GC—C receptor agonist and gut hormone fragment peptide YY 3-36 , glp-1 (glucagon-like peptide-1), exendin-4 (an inhibitor of glp-1), sibutramine, phentermine, phendimetrazine, benzphetamine hydrochloride (Didrex), orlistat (Xenical), diethylpropion hydrochloride (Tenuate), fluoxetine (Prozac), bupropion, ephedra, chromium, garcinia cambogia, benzocaine, bladderwrack (focus vesiculosus), chitosan, nomame herba, galega (Goat's Rue, French Lilac), conjugated linoleic acid, L-carnitine, fiber (psyllium, plantago, guar fiber), caffeine, dehydroepiandrosterone, germander (teucrium chamaedrys), B-hydroxy-,-methylbutyrate, or pyruvate.
66 . A method for treating congestive heart failure comprising administering the peptide of any of claims 1 , 16 - 19 and 24 and a natriuretic peptide such as atrial natriuretic peptide, brain natriuretic peptide, a C-type natriuretic peptide, a diuretic, or an inhibitor of angiotensin converting enzyme.
67 . A method for treating benign prostatic hyperplasia comprising administering the peptide of any of claims 1 , 16 - 19 and 24 and a 5-alpha reductase inhibitor or an alpha adrenergic inhibitor.
68 . A method for treating obesity comprising administering the peptide of any of claims 1 , 16 - 19 and 24 and gut hormone fragment peptide YY 3-36 , glp-1 (glucagon-like peptide-1), exendin-4 (an inhibitor of glp-1), sibutramine, phentermine, phendimetrazine, benzphetamine hydrochloride (Didrex), orlistat (Xenical), diethylpropion hydrochloride (Tenuate), fluoxetine (Prozac), bupropion, ephedra, chromium, garcinia cambogia, benzocaine, bladderwrack (focus vesiculosus), chitosan, nomame herba, galega (Goat's Rue, French Lilac), conjugated linoleic acid, L-carnitine, fiber (psyllium, plantago, guar fiber), caffeine, dehydroepiandrosterone, germander (teucrium chamaedrys), B-hydroxy-β-methylbutyrate, or pyruvate.
69 . A method for treating congestive heart failure comprising administering a GC—C receptor agonist and a natriuretic peptide such as atrial natriuretic peptide, brain natriuretic peptide, a C-type natriuretic peptide, a diuretic, or an inhibitor of angiotensin converting enzyme.
70 . A method for treating benign prostatic hyperplasia comprising a GC—C receptor agonist and a 5-alpha reductase inhibitor or an alpha adrenergic inhibitor.
71 . A method for treating obesity comprising administering a GC—C receptor agonist and gut hormone fragment peptide YY 3-36 , glp-1 (glucagon-like peptide-1), exendin-4 (an inhibitor of glp-1), sibutramine, phentermine, phendimetrazine, benzphetamine hydrochloride (Didrex), orlistat (Xenical), diethylpropion hydrochloride (Tenuate), fluoxetine (Prozac), bupropion, ephedra, chromium, garcinia cambogia, benzocaine, bladderwrack (focus vesiculosus), chitosan, nomame herba, galega (Goat's Rue, French Lilac), conjugated linoleic acid, L-carnitine, fiber (psyllium, plantago, guar fiber), caffeine, dehydroepiandrosterone, germander (teucrium chamaedrys), B-hydroxy-β-methylbutyrate, or pyruvate.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.